Merck's Earnings: A Beat on the Quarter, a Miss on the Outlook

The market's verdict on Merck's fourth quarter was a classic case of "buy the rumor, sell the news." The company delivered a clear beat on the quarter, but the stock's reaction was muted because the real focus was always on what was priced in for the future.

On the surface, the print was solid. For the quarter, Merck posted worldwide sales of $16.4 billion, a 5% year-over-year increase that topped the FactSet consensus of $16.2 billion. More importantly, the bottom line came in at adjusted EPS of $2.04, a significant jump from the prior year and well above the expected $1.93. This beat was driven by strength in oncology and animal health, with Keytruda sales rising 7% to $8.4 billion and new launches like Winrevair and Capvaxive contributing.

Yet, the whisper number for the quarter was already high, and the company's forward guidance reset the bar far lower. For 2026, Merck is now projecting worldwide sales between $65.5 billion and $67.0 billion and adjusted EPS between $5.00 and $5.15. This outlook is notably below the FactSet consensus of $67.4 billion in revenue and $5.27 in EPS. The guidance range is a clear reset, acknowledging the challenges ahead, including the patent cliff for Keytruda and the ongoing decline in Gardasil sales.

This is the core expectation gap. The market had priced in a strong quarter, and Merck delivered it. But the guidance for the coming year was the real story, and it was a disappointment. As one analyst noted, the focus was always going to be on the optics of the 2026 guide, and it came in below street consensus. The stock's slight gain on the news reflects this dynamic: the beat was already priced in, so the sell-off in forward-looking expectations overshadowed the good news from the past. The setup now hinges on whether the company's pipeline and acquisitions can close the gap between this lowered guidance and what investors will need to see to re-rate the stock higher.

The Guidance Reset: What's Priced In?

The lowered outlook is a direct result of a known, multi-year storm. The market's focus now is on whether these specific headwinds are already reflected in the stock's recent performance.

The most immediate hit is the one-time charge from the Cidara acquisition. Merck's guidance explicitly includes a one-time charge of roughly $9 billion, or around $3.65 per share. This massive, non-recurring expense is the primary driver pulling the 2026 adjusted EPS forecast down to $5.00-$5.15, well below the street's $5.36 expectation. This is a clean accounting reset, not a surprise.

Beyond that, the company is facing a wave of patent expirations. Later this year, the diabetes drugs Januvia and Janumet and the surgical drug Bridion will lose patent protection, opening the door to generic competition and pressuring sales. These are not blockbuster products like Keytruda, but their combined decline adds to the near-term pressure.

The real long-term overhang, however, is for Keytruda itself. A key U.S. patent for Keytruda is set to expire at the end of 2028. More critically, the drug is already slated for Inflation Reduction Act "government price setting" process in 2026, with negotiated prices taking effect in 2028. This dual threat-loss of exclusivity and mandated price cuts-creates a clear trajectory for the drug's sales growth to slow sharply starting next year.

So, are these concerns priced in? The stock's recent behavior suggests a partial reset. Shares have held near their current level despite the guidance miss, and the stock gained 10% since the start of February even as investors digested the news. This resilience hints that some of the negative outlook was already in the price, particularly the long-anticipated Keytruda patent cliff. The market seems to be focusing on the pipeline catalysts and the company's diversification efforts to offset the coming losses. Yet, the guidance reset itself-especially the sharp EPS drop and the specific timing of the IRA price setting-still represents a tangible negative surprise that the stock has not yet fully digested. The expectation gap is narrowing, but it hasn't closed.

Catalysts and Risks: The Path to 2028

The stock's recent volatility shows the market is actively weighing the new reality. Shares gained 10% since the start of February, a move that likely reflected initial relief that the Q4 beat was delivered. But that rally has since faded, with the stock down nearly 2% over the past five days. This choppiness is a classic reaction to a guidance reset-it's the market testing whether the positive news from the past quarter is enough to offset the negative outlook for the future. The setup is now one of high sensitivity to any new data on Keytruda's trajectory or pipeline progress.

The primary structural risk is the clear path to a "Keytruda cliff" starting in 2028. The drug's key U.S. patent is set to expire at the end of 2028, opening the door to biosimilar competition. More immediately, the Inflation Reduction Act's "government price setting" process will begin in 2026, with negotiated prices taking effect in 2028. This dual threat-a loss of exclusivity and mandated price cuts-creates a near-certain trajectory for Keytruda's sales growth to slow sharply next year. The market has priced in this long-term decline, but the stock remains vulnerable to any acceleration in that pressure.

Merck's strategy to offset these losses hinges on two pillars: acquisitions and new launches. The company has already made major moves, with the acquisitions of Verona Pharma and Cidara Therapeutics aimed at bolstering its respiratory and anti-infective portfolios. The early sales from these new assets are contributing, with WINREVAIR sales at $1.4 billion and CAPVAXIVE at $759 million in the quarter. The success of these integrations and the launch of other pipeline candidates, like enlicitide and sacituzumab tirumotecan, will be critical to filling the gap. The expectation gap for 2028 is not just about Keytruda's decline, but about whether Merck's portfolio transformation can deliver a credible, high-growth replacement.